Prima BioMed Ltd. announced the formation of a Clinical Advisory Board (CAB) to serve as a strategic resource to the company as it continues to advance the clinical development program and commercialisation path for its lead drug candidate IMP321 for cancer patients worldwide. The CAB will advise Prima on the regulatory and clinical development strategy for its Active Immunotherapy PAClitaxel (AIPAC) clinical trial, which is investigating the safety and efficacy of IMP321 active immunotherapy in combination with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer. The newly formed board will be chaired by Pr. Martine Piccart, who will be joined by Doctor Luc Dirix, Professor David Cameron, Doctor Samson Fung, and Professor Salah-Eddin Al-Batran. Professor Martine J. Piccart is professor of oncology at the Université Libre de Bruxelles (ULB) and Head of the medicine department at the Institute Jules Bordet, in Brussels, Belgium. Doctor Luc Dirix is Head of Medical Oncology at the Oncology Center at AZ Sint-Augustinus Hospital in Antwerp, Belgium. Professor David Cameron is the Clinical Director and Chair of Oncology at The University of Edinburgh Cancer Research Centre in the UK. Doctor Samson Fung of Fung Consulting in Germany, provides strategic and operational assistance to pharmaceutical and biotech companies including Novartis and Bristol-Myers- Squibb. Professor Salah-Eddin Al-Batran is the Medical Director at the Institute of Clinical Cancer Research in Frankfurt, Germany.